John W. Ostrominski, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 12 | 2023 | 10900 | 1.860 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2023 | 132 | 0.790 |
Why?
|
| Ventricular Function, Left | 6 | 2023 | 3670 | 0.740 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 5751 | 0.730 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 349 | 0.670 |
Why?
|
| Stroke Volume | 8 | 2023 | 5007 | 0.650 |
Why?
|
| Symporters | 1 | 2020 | 362 | 0.600 |
Why?
|
| Prediabetic State | 1 | 2022 | 499 | 0.580 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 11725 | 0.520 |
Why?
|
| Myocytes, Cardiac | 2 | 2020 | 1637 | 0.480 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2023 | 1265 | 0.480 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2020 | 1736 | 0.470 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 15165 | 0.460 |
Why?
|
| Endothelium, Vascular | 2 | 2022 | 4456 | 0.450 |
Why?
|
| Heart Transplantation | 2 | 2023 | 3110 | 0.420 |
Why?
|
| Kidney Diseases | 1 | 2023 | 2149 | 0.410 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2208 | 0.350 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 11727 | 0.230 |
Why?
|
| Hypertension | 1 | 2023 | 8480 | 0.230 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 85 | 0.220 |
Why?
|
| Cardiac Myosins | 1 | 2023 | 117 | 0.220 |
Why?
|
| Humans | 23 | 2023 | 744343 | 0.190 |
Why?
|
| Conservation of Natural Resources | 1 | 2023 | 204 | 0.190 |
Why?
|
| Stress, Mechanical | 2 | 2022 | 1686 | 0.190 |
Why?
|
| New York | 1 | 2022 | 886 | 0.180 |
Why?
|
| Biphenyl Compounds | 1 | 2023 | 913 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13102 | 0.160 |
Why?
|
| Drug Combinations | 1 | 2023 | 1959 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2023 | 859 | 0.150 |
Why?
|
| Founder Effect | 1 | 2018 | 189 | 0.150 |
Why?
|
| Sodium | 1 | 2023 | 1623 | 0.150 |
Why?
|
| Tetrazoles | 1 | 2023 | 835 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2023 | 845 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 924 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2023 | 1530 | 0.150 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 1660 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1518 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2023 | 1167 | 0.140 |
Why?
|
| Dependovirus | 2 | 2018 | 706 | 0.130 |
Why?
|
| Dyspnea | 1 | 2023 | 1303 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 913 | 0.120 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 522 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2023 | 2240 | 0.110 |
Why?
|
| Transfection | 1 | 2020 | 5892 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2020 | 1153 | 0.100 |
Why?
|
| Aspirin | 1 | 2023 | 3282 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 2872 | 0.100 |
Why?
|
| Glucose | 1 | 2023 | 4397 | 0.100 |
Why?
|
| Health Status | 1 | 2023 | 4034 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2021 | 3209 | 0.080 |
Why?
|
| Decision Making | 1 | 2022 | 3887 | 0.080 |
Why?
|
| Registries | 1 | 2022 | 8089 | 0.070 |
Why?
|
| Prevalence | 1 | 2023 | 15226 | 0.070 |
Why?
|
| Risk Factors | 2 | 2023 | 72290 | 0.070 |
Why?
|
| Hospitalization | 2 | 2023 | 10262 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2020 | 11483 | 0.070 |
Why?
|
| Disease Progression | 1 | 2022 | 13284 | 0.070 |
Why?
|
| Calcium | 1 | 2018 | 5756 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18029 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25043 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2023 | 23338 | 0.050 |
Why?
|
| Middle Aged | 4 | 2023 | 213383 | 0.050 |
Why?
|
| Macaca mulatta | 2 | 2018 | 2375 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 12745 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2023 | 40561 | 0.050 |
Why?
|
| Stage-Specific Embryonic Antigens | 1 | 2018 | 6 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 53288 | 0.040 |
Why?
|
| Female | 4 | 2023 | 380194 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2018 | 223 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2018 | 418 | 0.040 |
Why?
|
| Mice | 2 | 2020 | 81183 | 0.030 |
Why?
|
| Demography | 1 | 2020 | 1656 | 0.030 |
Why?
|
| Fluorescence | 1 | 2018 | 751 | 0.030 |
Why?
|
| Aged | 2 | 2023 | 163280 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 77449 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 1547 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 168757 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2023 | 2531 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 850 | 0.020 |
Why?
|
| Male | 3 | 2023 | 350118 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 2382 | 0.020 |
Why?
|
| Adult | 1 | 2023 | 214055 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2018 | 2575 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2018 | 3420 | 0.020 |
Why?
|
| Gene Expression | 1 | 2018 | 7799 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 15997 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 57776 | 0.010 |
Why?
|
| United States | 1 | 2020 | 69872 | 0.010 |
Why?
|